These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 4427222)

  • 21. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 22. The learned intermediary doctrine: past, present and future.
    Alsobrook HB
    Leg Med; 1994; ():269-80. PubMed ID: 7830482
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic orphans.
    Shirkey H
    Pediatrics; 1999 Sep; 104(3 Pt 2):583-4. PubMed ID: 10469793
    [No Abstract]   [Full Text] [Related]  

  • 24. Therapeutic orphans: European perspective.
    Assael BM
    Pediatrics; 1999 Sep; 104(3 Pt 2):591-2. PubMed ID: 10469795
    [No Abstract]   [Full Text] [Related]  

  • 25. [Survey of 50 years of veterinary remedy provision in the Netherlands].
    van den Bos T
    Tijdschr Diergeneeskd; 1998 Dec; 123(24):743-8. PubMed ID: 9879623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. A pharmaceutical industry perspective on drug labeling.
    Robinson DS
    Psychopharmacol Bull; 1994; 30(1):23-5. PubMed ID: 7972625
    [No Abstract]   [Full Text] [Related]  

  • 27. How the Kennedy drug bill could affect the physician's practice. A critique of the Drug Utilization improvement Act of 1974 (S 3441).
    Brennan BJ
    J Leg Med (N Y); 1974; 2(4):25-8. PubMed ID: 4546431
    [No Abstract]   [Full Text] [Related]  

  • 28. A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule.
    Connor JD
    Pediatrics; 1999 Sep; 104(3 Pt 2):610-3. PubMed ID: 10469801
    [No Abstract]   [Full Text] [Related]  

  • 29. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 30. Development of orphan products.
    FDA Drug Bull; 1983 Apr; 13(1):2-4. PubMed ID: 6852406
    [No Abstract]   [Full Text] [Related]  

  • 31. New drug development in the changing health care environment: a panel discussion.
    Flanagan A; Temple RJ; Wardell WM
    Ann N Y Acad Sci; 1981; 368():203-11. PubMed ID: 6942776
    [No Abstract]   [Full Text] [Related]  

  • 32. Government investigations in the pharmaceutical industry: off-label promotion, fraud and abuse, and false claims.
    Kalb PE; Bass IS
    Food Drug Law J; 1998; 53(1):63-70. PubMed ID: 11795337
    [No Abstract]   [Full Text] [Related]  

  • 33. A survey of developments in food and drug law from July 1998 to November 1999.
    Littlefield N; Hada NR
    Food Drug Law J; 2000; 55(1):35-56. PubMed ID: 12296348
    [No Abstract]   [Full Text] [Related]  

  • 34. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 35. Editorial: drug scandal.
    Mukerjee AB
    J Indian Med Assoc; 1974 May; 62(9):326-8. PubMed ID: 4436552
    [No Abstract]   [Full Text] [Related]  

  • 36. Spurious and counterfeit drugs: a growing industry in the developing world.
    Gautam CS; Utreja A; Singal GL
    Postgrad Med J; 2009 May; 85(1003):251-6. PubMed ID: 19520877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dietary supplements: background for dialogue between the industry and the medical profession.
    Friede AI
    Food Drug Law J; 1998; 53(3):413-20. PubMed ID: 10346719
    [No Abstract]   [Full Text] [Related]  

  • 38. Editorial: On immunization warnings.
    Trout ME
    J Leg Med (N Y); 1975 Apr; 3(4):7. PubMed ID: 1079232
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial: Some caveats for the FDA.
    Calif Med; 1973 Oct; 119(4):64-5. PubMed ID: 4749314
    [No Abstract]   [Full Text] [Related]  

  • 40. When you have a hammer everything looks like a nail: misapplication of the False Claims Act to off-label promotion.
    Hall RF; Berlin RJ
    Food Drug Law J; 2006; 61(4):653-77. PubMed ID: 17180768
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.